The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•8 April 2026•

1 min read

Amgen Retains Neutral Rating at Cantor Fitzgerald Amid Positive Clinical Data

A man in a suit over a stock chart with 'Mondelez International' text, surrounded by chocolate, cocoa beans, factories, and shops.

Key Facts

1Cantor Fitzgerald maintained a Neutral rating and a $350.00 price target on Amgen Inc.

2Anticipated beats in key commercial drivers like Repatha and Uplizna for Q1 2026 earnings.

Cantor Fitzgerald has reaffirmed its 'Neutral' rating on Amgen Inc. (AMGN) with a price target of $350.00 as the company prepares for its Q1 2026 earnings release. Analysts anticipate that key commercial drivers, specifically Repatha and Uplizna, will exceed market expectations in the upcoming financial report. The biotech giant recently announced successful Phase 3 trial results for TEPEZZA, a treatment for Thyroid Eye Disease, further bolstering investor confidence. While Cantor Fitzgerald remains cautious, other firms like William Blair and RBC Capital have reiterated 'Outperform' ratings following the clinical success. The combination of strong product momentum and positive trial outcomes provides a favorable backdrop for the stock. Investors are now closely monitoring the upcoming earnings call for further updates on the company's pipeline and commercial strategy.